SecBot SecBot
8-K ·Filed Nov 5, 2026

NTRA

Natera, Inc.
MIXED
Impact 6/10
Horizondays Processed6d 5h ago SEC0001604821-26-000032
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The strong revenue beat and guidance raise signal accelerating commercial momentum, particularly in oncology MRD, but the EPS miss due to rising R&D and SG&A spend warrants monitoring of expense trajectory. Watch for operating leverage as revenue scales and for progress toward profitability.

DirectionMixed
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$310.67
T+0 close · Nov 5, 2026 · via day close
Latest settled
+3.13%
T+1 · $320.39
vs SPY
+0.76%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 6 $310.67entry
  2. T+1 · 3d ago +3.13%α +0.76% · $320.39
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 25d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Natera reported Q3 2026 revenue of $794.0M (+34.1% YoY), beating the $707.5M consensus, and raised full-year 2026 revenue guidance by $140M at the midpoint to $3.005B-$3.035B. However, GAAP EPS of -$0.42 missed the consensus estimate of -$0.28 by 50%, driven by higher operating expenses. The strong revenue beat and guidance raise are offset by the EPS miss.

Key Financial Metrics

EPS
−$0.42
est −$0.28 · -50.0%
Revenue
$794.0M
est $707.5M · +12.2% · +34.1% YoY
Rating
in line
Guidance
$3.005B-$3.035B
raised
Gross Margin
64.7%

Key Facts

  • Q3 2026 total revenue of $794.0M, up 34.1% YoY from $592.2M
  • GAAP net loss of $59.9M or ($0.42) per diluted share vs ($0.64) in Q3 2025
  • GAAP EPS of ($0.42) missed consensus of ($0.28) by 50%
  • Revenue of $794.0M beat consensus of $707.5M
  • Raised 2026 annual revenue guidance by $140M at midpoint to $3.005B-$3.035B
  • Gross margin of 64.7% vs 64.9% in Q3 2025; ex-true-ups non-GAAP gross margin up ~140 bps sequentially
  • Processed ~1,093,100 total tests (+22.3% YoY) and ~339,500 oncology tests (+60.9% YoY)
  • Clinical MRD oncology units grew ~33K sequentially to ~316K
  • Cash increased by $5.7M from Q2 2026 to $1,097.2M
  • Operating loss improved to $68.3M from $97.6M in Q3 2025

Financial Impact

Revenue beat consensus by $86.5M (+12.2%); EPS miss by $0.14 (-50%); full-year revenue guidance raised by $140M at midpoint

revenueepsguidancegross margin

Risk Factors

  • EPS miss of 50% versus consensus may pressure the stock despite revenue beat
  • Rising operating expenses (R&D +19.5% YoY, SG&A +8.2% YoY) are outpacing revenue growth in absolute dollars
  • Company remains unprofitable with net loss of $59.9M in the quarter
  • Gross margin declined slightly YoY (64.7% vs 64.9%) and benefited from revenue true-ups that may not recur

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
90% bullish (31 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001604821-26-000032
Document: ntra-20261105.htm0001604821-26-000032
Document: ntra-20260930xex992.htm0001604821-26-000032
Document: 0001604821-26-000032-index-headers.html0001604821-26-000032
Document: 0001604821-26-000032-index.html0001604821-26-000032
Document: 0001604821-26-000032.txt0001604821-26-000032
8-K Data (Synthetic)0001604821-26-000032

Track record

61 reports on NTRA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +6.55% at T+5 after the Oct 2, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 10, 20261d ago Insider Cluster Neutral 3/10 Entry $318.65 Now $311.98 −2.09% settles Nov 12
  2. Nov 6, 20265d ago SC 13G/A Neutral 3/10 Entry $310.67 to $320.39 Now $311.98 +0.42% ▲ +3.13% +0.76% vs SPY
  3. Nov 5, 20266d ago 8-K Mixed 6/10 Viewing Entry $310.67 to $320.39 Now $311.98 +0.42% ▲ +3.13% +0.76% vs SPY
  4. Nov 5, 20266d ago SC 13G Neutral 4/10 Entry $363.76 to $310.67 Now $311.98 −14.23% ▼ −14.59% −14.91% vs SPY
  5. Nov 4, 20266d ago Insider Cluster Neutral 2/10 Entry $363.76 to $310.67 Now $311.98 −14.23% ▼ −14.59% −14.91% vs SPY
  6. Nov 3, 20268d ago 144 Neutral 2/10 Entry $391.03 to $363.76 Now $311.98 −20.22% ▼ −6.97% −2.56% vs SPY
  7. Nov 2, 20269d ago 144 Neutral 2/10 Entry $388.63 to $391.03 Now $311.98 −19.72% ▲ +0.62% −1.03% vs SPY
  8. Nov 2, 20269d ago 144 Neutral 3/10 Entry $388.63 to $391.03 Now $311.98 −19.72% ▲ +0.62% −1.03% vs SPY
  9. Nov 2, 20269d ago 144 Neutral 1/10 Entry $388.63 to $391.03 Now $311.98 −19.72% ▲ +0.62% −1.03% vs SPY
  10. Nov 2, 20269d ago 144 Neutral 2/10 Entry $388.63 to $391.03 Now $311.98 −19.72% ▲ +0.62% −1.03% vs SPY
Showing 10 of 61

US Market Status

Market Closed · Opens Fri (11h 58m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026